A new report by the Good Food Institute APAC finds that China's largest fermentation manufacturers are redirecting capacity toward mycoprotein, yeast proteins, and precision-fermented fats as pharmaceutical margins shrink.

Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and